MIBOLERONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H30O2
Molecular Weight	302.451
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4C[C@@H](C)[C@@]23[H]

InChI

InChIKey=PTQMMNYJKCSPET-OMHQDGTGSA-N

InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C20H30O2
Molecular Weight	302.451
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2422638
Curator's Comment: Description was created based on several sources, including http://www.skylocke.com/pdf_txt/CHEQUE-Drops.PDF | https://www.ncbi.nlm.nih.gov/pubmed/18515094 | https://anabolic.org/cheque-drops-mibolerone/

Mibolerone is a synthetic anabolic steroid. It binds both androgen and progesterone receptors and exerts both androgenic and progestagenic actions. Mibolerone (CHEQUE® Drops) was used in veterinary for estrous (heat) prevention in adult female dogs not intended primarily for breeding purposes. No prescription preparation, human or veterinary, is currently known to contain mibolerone worldwide.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen Receptor 167 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2422638 \| https://www.ncbi.nlm.nih.gov/pubmed/10077001 \| https://www.ncbi.nlm.nih.gov/pubmed/18515094	Agonist 2678		1.5 nM [Kd]
Progesterone receptor 61 Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2422638 \| https://www.ncbi.nlm.nih.gov/pubmed/18515094 \| https://www.ncbi.nlm.nih.gov/pubmed/9228646	Agonist 2678		5.9 nM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578

PubMed

Title	Date	PubMed
Activation of androgen receptor in epidermal growth factor modulation of fetal mouse sexual differentiation.	1996 Oct 14	8912815
Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells.	1999 Dec 1	10606230
A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells.	1999 Nov	10537180
Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene.	2000 Jun	10852459
Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor.	2001 Jul	15111251
Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons.	2001 Jun	11389183
Recombinant expression and purification of human androgen receptor in a baculovirus system.	2001 Jun 15	11396977
Role of androgens in female genital sexual arousal: receptor expression, structure, and function.	2002 Apr	12007897
Effect of geldanamycin on androgen receptor function and stability.	2002 Jan	11894840
Effects of a diphenyl ether-type herbicide, chlornitrofen, and its amino derivative on androgen and estrogen receptor activities.	2003 Apr	12676605
Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.	2003 Nov 15	14633711
Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth.	2004 Feb 23	14970875
Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter.	2004 Mar	15001595
Estimation of estrogenic and antiestrogenic activities of selected pesticides by MCF-7 cell proliferation assay.	2004 May	15253041
Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription.	2004 May	15141018
Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.	2004 Nov 4	15509168
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.	2004 Oct 1	15466214
Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.	2005 Apr	15661808
Stem/progenitor and intermediate cell types and the origin of human prostate cancer.	2005 Dec	16351690
[Regulation of expression of pituitary tumor transforming gene 1 (PTTG1) by androgen in prostate cancer].	2005 Dec 18	16378119
The Estradiol-Dihydrotestosterone model of prostate cancer.	2005 Mar 18	15777479
Androgen-induced mineralization by MC3T3-E1 osteoblastic cells reveals a critical window of hormone responsiveness.	2005 Mar 18	15694414
Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation.	2005 Sep	16140617
COMPRENDO: Focus and approach.	2006 Apr	16818253
Collision-induced dissociation pathways of anabolic steroids by electrospray ionization tandem mass spectrometry.	2006 Apr	16488153
Contraception in felids.	2006 Jul 1	16626799
Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells.	2006 May 18	16029925
Expression and function of the human androgen-responsive gene ADI1 in prostate cancer.	2007 Aug	17786183
Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells.	2007 Feb 1	17075824
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.	2007 Jul 17	17606915
Steroids with a carbamate function at C-17, a novel class of inhibitors for human and hamster steroid 5alpha-reductase.	2007 Oct	17629476
Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents.	2007 Sep	17723170
Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects.	2008	18978937
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors.	2008 Jun	18515094
Steroid and beta-adrenergic receptor modifications in target organs of broiler chickens fed with a diet containing beta2-adrenergic agents.	2008 Jun	18407392
In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.	2008 Sep	18644453
Synthesis and biological effect of halogen substituted phenyl acetic acid derivatives of progesterone as potent progesterone receptor antagonists.	2008 Sep	18625316
Biological activity of novel progesterone derivatives having a bulky ester side chains at C-3.	2008 Sep	18472120
Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.	2009 Dec	19635783
Androgen receptor mutations associated with androgen insensitivity syndrome: a high content analysis approach leading to personalized medicine.	2009 Dec 9	20011049
Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors.	2009 Jun	18825535
Novel C-6 substituted and unsubstituted pregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size.	2009 Oct	19406144
Regulation of growth hormone receptors in human prostate cancer cell lines.	2009 Oct 15	19540305
A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells.	2010 Dec 5	20692244
Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells.	2010 Sep 9	21364676
Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.	2015 Jul 3	25846647

Patents

Sample Use Guides

In Vivo Use Guide

CHEQUE® DROPS mibolerone 100 ug/ml female dogs: 1 to 25 lbs - 30 ug, 26 to 50 lbs - 60 ug, 51 to 100 lbs - 120 ug, 101 and over lbs - 180 ug orally once each day by adding to a small amount of food or directly to the mouth

Route of Administration: Oral

In Vitro Use Guide

Whereas high physiological doses (10-100nM) of 5alpha-dihydrotestosterone reduced E(2)-mediated induction of the estrogen-regulated gene progesterone receptor (PR) to basal levels, mibolerone at lower doses (1nM) eliminated PR expression, suggesting that mibolerone may also act via the PR.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:03:20 GMT 2023` Edited by `admin` on `Sat Dec 16 16:03:20 GMT 2023`
Record UNII	9OGY4BOR8D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MIBOLERONE

Official Name

English

NSC-72260

Code

English

MIBOLERONE [GREEN BOOK]

Common Name

English

MIBOLERONE CIII

Common Name

English

MIBOLERONE [MI]

Common Name

English

U-10,997

Code

English

U-10997

Code

English

17β-Hydroxy-7α,17-dimethylestr-4-en-3-one

Systematic Name

English

MIBOLERONE [USP MONOGRAPH]

Common Name

English

MIBOLERONE [USAN]

Common Name

English

MIBOLERONE [MART.]

Common Name

English

MIBOLERONE CIII [USP-RS]

Common Name

English

U-10-997

Code

English

MATENON

Brand Name

English

ESTR-4-EN-3-ONE, 17-HYDROXY-7,17-DIMETHYL-, (7.ALPHA.,17.BETA.)-

Common Name

English

DIHYDROLONE

Common Name

English

CHEQUE DROPS

Brand Name

English

CHEQUE

Brand Name

English

mibolerone [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C243